The enteric nervous system (ENS) represents a vast network of neuronal and glial cell types that develops entirely from migratory neural crest (NC) progenitor cells. Considerable improvements in the understanding of the molecular mechanisms underlying NC induction and regional specification have recently led to the development of a robust method to re-create the process in vitro using human pluripotent stem cells (hPSCs). Directing the fate of hPSCs toward the enteric NC (ENC) results in an accessible and scalable in vitro model of ENS development. The application of hPSCderived enteric neural lineages provides a powerful platform for ENS-related disease modeling and drug discovery. Here we present a detailed protocol for the induction of a regionally specific NC intermediate that occurs over the course of a 15-d interval and is an effective source for the in vitro derivation of functional enteric neurons (ENs) from hPSCs. Additionally, we introduce a new and improved protocol that we have developed to optimize the protocol for future applications in regenerative medicine, in which components of undefined activity have been replaced with fully defined culture conditions. This protocol provides access to a broad range of human ENS lineages within a 30-d period.
Introduction
During embryogenesis, NC induction occurs at the interface of the non-neuronal ectoderm and the folding neural plate as a result of bone morphogenic protein (BMP), fibroblast growth factor (FGF), and Wnt signaling pathway activity 1 . During neurulation, dorsally localized NC cells delaminate and migrate away from the newly formed neural tube. Migratory NC cells proliferate and act as progenitors for a remarkable diversity of cell types, including various populations of peripheral neurons and glia, melanocytes, endocrine cells, and mesenchymal precursor cells [1] [2] [3] . In the developing embryo, the NC shows an anterior-posterior spatial organization associated with the expression of regionally specific HOX genes. Distinct functional regions include the cranial NC, vagal NC, trunk NC, and sacral NC located anteriorly to posteriorly, respectively (Fig. 1) .
While the ENS is generated from both the vagal and sacral NC, vagal NC lineages positive for HOXB3 (ref. 4 ) and HOXB5 (ref. 5 ) migrate most extensively to colonize the entire length of the bowel 6 (blue and green arrows in Fig. 1 ). After their inclusion in the foregut, vagal NC cells display ENC identity characterized by the expression of SOX10, PHOX2B, EDNRB, and ASCL1. Colonization of the intestinal tract by the ENC has been depicted as a rostrocaudally moving wave of proliferative multipotent ENS progenitors 7 . By week 7 of embryogenesis in humans, migratory ENC cells reach the terminal hindgut 8 . Failure of ENC migration to the caudal regions of the bowel can result in congenital aganglionosis of the colon, a disorder known as Hirschsprung's disease.
Post-migratory ENC cells will commit to neuronal fates; a differentiation step associated with the downregulation of SOX10; sustained expression of EDNRB, ASCL1, and PHOX2B; and upregulation of pan-neuronal markers such as TUJ1 (ref. 9 ). ENC progenitors further differentiate to establish ganglia located between the circular and longitudinal layers of enteric smooth muscle, forming the myenteric plexus. Recent spatiotemporal analysis of the murine ENS has shown that ENC progenitors within the myenteric plexus proliferate along the serosa-mucosal axis to subsequently form the ganglia of the submucosal plexus 10 . Together, the myenteric and submucosal plexi establish the neuronal circuitry of the functional ENS.
Owing to the capacity of the NC to undergo an extensive range of cell-fate decisions, methods seeking to optimize NC induction and subtype specification from hPSCs have been an important focus of research [11] [12] [13] . hPSC-based protocols to derive NC commonly rely on a variation of the dual SMAD-signaling inhibition protocol for neural induction, combined with the temporal activation of Wnt signaling 12, 14 . However, such methods often involve the use of poorly defined culture components, such as serum, BSA fractions, and other animal-derived products, which may affect the reliability and reproducibility of the NC induction step. Accordingly, our group and others have recently reported protocols that use fully defined, xeno-free culture conditions for the reliable induction of cranial NC from hPSCs 15, 16 . Here we present step-by-step instructions for both our previously published protocol 14 (option A in Steps 7 and 8) and a similar but fully defined differentiation protocol (option B in Steps 7 and 8) that integrates retinoic acid (RA) treatment to effectively transition the induction of cranial NC to a specific vagal NC regional identity 14 .
Applications
The spatial and temporal transience of the ENC has been a major factor limiting access to primary cells, particularly from human embryonic or fetal tissue samples. As a result, studying the developing ENS has largely relied on studies in murine models. Work with such murine models resulted in the discovery of growth factors involved in the proliferation and differentiation of EN precursors, such as neurotrophin-3 (NT-3) and glial-cell-line-derived neurotrophic factor (GDNF) 17, 18 , among others. More recent single-cell transcriptomics analysis of the developing murine ENS has revealed novel molecular states of lineally and functionally related ENS progenitors 10 . An appreciable conservation of the transcriptional processes underpinning ENS development across mammals 19 supports the application of these factors to direct hPSC-derived ENC cells toward neurogenic commitments and may help further guide the identification, characterization, and derivation of human enteric neuronal subtype lineages. A reliable protocol for the stepwise derivation of ENs from hPSCs provides the basis for modeling ENS development and the contribution of specific lineages to ENS disease.
A reliable protocol for the stepwise derivation of ENS lineages from hPSCs can be used in multiple research applications. The genetic contributions underpinning ENS pathogenesis can be probed through the use of induced pluripotent stem cell (iPSC) lines generated from individuals with enteric neuropathies 20 . Disease phenotypes can be modeled through in vitro differentiations and addressed via genetic or molecular perturbation strategies. Under the minimal, highly defined conditions of this protocol, it may be possible to further expand the understanding of how precise perturbations affect cell-fate commitments of EN progenitors and recapitulate disease phenotypes exhibited by EN lineages. Similarly, a scalable platform that produces unlimited numbers of hPSC-derived ENC cells or ENs on demand could allow for high-throughput screening assays that were previously unworkable. Therefore, such a protocol opens the door to testing the effects of large libraries of compounds or genes on fate commitment or the selective vulnerability of ENS lineages.
We have previously shown that hPSC-derived ENC cells can engraft in the murine host colon and differentiate into functional ENs 14 . Looking forward, several enteric neuropathies of the 
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gastrointestinal tract have been described as potential targets for EN cell transplantation 21 . Option B in Steps 7 and 8 sets a new standard in presenting a method to derive ENs from hPSCs under highly defined conditions as a step toward the production of clinical-grade cells suitable for translational applications in the treatment of enteric neuropathies. Much remains to be understood in terms of the ideal cell type, state of differentiation, and optimal delivery method used to replace damaged or absent cells in enteric neuropathies, but such translational applications present a rational strategy for preclinical development and an exciting area of research.
Comparison with other methods
The protocol described here presents the evolution of our previously published work and stands amid a limited set of previously reported methods for the derivation of enteric neural progenitors from pluripotent stem cells 22 . Many labs in the stem cell field no longer rely on the support of feeder cells and have adopted the use of defined basal media such as mTeSR1 and Essential 8 (E8) for the maintenance of hPSC lines. Nevertheless, previous ENC induction methods commonly involved medium containing serum-replacement factors, namely, knockout serum replacement (KSR), as is also the case in Steps 7A and 8A 14, 20 . In an effort to reduce the inconsistencies and quality control measures that undefined conditions may introduce to a protocol, we optimized the ENC induction step under minimal, chemically defined conditions.
Recent studies have implemented alternative strategies for general NC induction using hPSCs, namely, free-floating embryoid-body-based approaches 23, 24 . The migratory cells that come as a result of embryoid body and subsequent neural rosette formations have been shown to be positive for NCspecific markers Sox10, TFAP2A, BRN3A, ISL1, and ASCL1, and a subset were found to be positive for regionally specific vagal markers HOXB2 and HOXB5, even without the inclusion of RA 23 . Overall, the NC induction efficiency was assessed by FACS of p75 and HNK1 double-positive cells, a strategy used to isolate NC cells in previous protocols 25 . The results showed >60% induction efficiency in ESC line H9 and across independent human iPSC (hiPSC) lines 23 . Enriched NC populations were then co-cultured with primary gut explants in a Transwell system to promote ENC identities enriched for HOXB2, HOXB3, HAND2, and EDNRB. Notably, this method incorporates brainderived neurotrophic factor, GDNF, nerve growth factor, and NT3 into the culture conditions. How these factors affect the commitments of EN precursors, namely, identities positive for VIP and calretinin 23 , remains an interesting point of inquiry. A similar embryoid body approach incorporated brief exposure to RA during NC induction before eventually combining hPSC-derived NC cells with hPSC-derived intestinal organoids 24 . In terms of ENC induction efficiency, data directly comparing monolayer and embryoid body strategies remain limited. Therefore, the optimal use of each strategy for a given application should be explored further.
Limitations
Despite the broad applicability and reliable outcomes of the protocol, there are limitations that should be considered. It has been shown that hPSC-derived ENs produced through both options A and B in Steps 7 and 8 comprise many neuronal subtypes resembling those found throughout the ENS in vivo 14 . However, the extent to which ENs derived in vitro accurately recapitulate those of the human ENS, in terms of both the developmental pathways taken by multipotent ENC progenitors and the connectivity established by post-mitotic neurons, warrants further exploration. Likewise, molecular characterization of the various neuronal subtype lineages generated through this protocol has been limited to a catalog of transcription factors and neurochemical identities 6, 26 . It will be highly valuable to compare the detailed molecular features of hPSC-derived EN lineages to those of primary human cells, such as by single-cell transcriptomics, to resolve how effectively they map onto the human ENS in vivo. Furthermore, the current protocol is focused on generating ENC lineages derived from the vagal NC, and it will be important to develop protocols to generate ENC lineages from hPSC-derived sacral NC.
Experimental design
Here we present a protocol for the derivation of EN lineages from hPSCs. As mentioned above, Steps 7 and 8 of this protocol present two parallel options, options A and B. The development and utility of option A was established previously in ref.
14 . The adoption of option B should be favored by users seeking to derive EN lineages via the most chemically defined and reliable method currently available. The important points of difference between options A and B are found in the maintenance of hPSCs (Step 7) and during the ENC induction phase (Step 8). The adoption of E8 for option B in both steps offers a chemically defined basal medium for the maintenance of hPSCs 27 , in place of the feeder cell and KSR medium used in option A. A transition from E8 to E6 basal medium, in conjunction with precise combinations of BMP and Wnt signaling, and the addition of RA, triggers the developmental cues required for ENC induction. In Step 8, option A requires gradual titration between relative amounts of basal media KSR and N-2, whereas option B utilizes a single defined basal medium, E6. Consequently, Step 8A involves dual SMAD inhibition using SB431542 and LDN-193189, whereas the conditions of Step 8B demand only inhibition of TGF-β signaling inhibition with SB431542. Notably, the replacement of the KSR used in Step 8A makes early activation of low levels of BMP signaling with BMP4 necessary to induce NC specification under the conditions of Step 8B. For both options, CHIR 99021 is used to activate canonical Wnt signaling, though lower concentrations are necessary when option B is selected in Steps 7 and 8, and for both options, RA is used to pattern NC cells toward the vagal ENC identity. We provide schematic illustrations outlining the induction conditions of options A (Supplementary Fig. 1) and B (Fig. 2a) for Steps 7 and 8.
To ensure optimal induction efficiency, hPSCs must be cultured under the maintenance conditions of either Steps 7A and 8A or Steps 7B and 8B for several passages before differentiation. A critical parameter that should be controlled and adjusted carefully is the density of hPSCs at the beginning of ENC induction. Independent batches of differentiated cells should be quality-controlled to ensure their ENC identity on the basis of gene expression and functional characteristics. It is also important to consider baseline variability among different hPSC lines in terms of differentiation efficiency (see 'Anticipated results'). Cell-line-specific optimization of culture density may be required when hPSCs with low baseline ENC-differentiation capacity are used.
Materials

Biological materials
• Human embryonic or induced pluripotent stem cell lines ! CAUTION Short tandem repeat (STR) profiling should be carried out on the hPSC lines to confirm their identity and ensure that they are not cross-contaminated. Regular karyotyping and frequent mycoplasma testing are necessary to monitor genomic stability and to avoid latent contamination. c CRITICAL The quality of hPSC lines used in your differentiations should be verified by routine characterization of pluripotency, including expression of markers such as NANOG and OCT4 and their ability to differentiate into endodermal, mesodermal, and ectodermal lineages. The cell lines that we used for this paper are hESC line H9 (WA-09) H9-derivative SOX10::GFP (WiCell Research Institute, Memorial Sloan Kettering Cancer Center), hESC line UCSF4 (University of California, San Francisco), and hiPSC line WTC11 (Coriell Institute, Gladstone Institute).
c CRITICAL Appropriate consent procedures and administrative regulations must be followed for work involving hESCs and hiPSCs. Please consult your institution to ensure adherence with national and institutional guidelines and regulations. • BMP-4 (recombinant human BMP-4 protein; R&D Systems, cat. no. 314-BP) c CRITICAL Stock aliquots should be stored at -80°C. One aliquot should be kept at 4°C to avoid multiple freeze/thaw cycles and used within 4 weeks.
• CHIR 99021 (Tocris, cat. no. 4423) c CRITICAL Stock aliquots should be stored at -20°C. One aliquot should be kept at 4°C and used within 4 weeks.
• FGF2 (recombinant human FGF basic; R&D Systems, cat. no. 233-FB) c CRITICAL Stock aliquots should be stored at -80°C. One aliquot should be kept at 4°C to avoid multiple freeze/thaw cycles and used within 4 weeks.
• GDNF (recombinant human glial-derived neurotrophic factor; Peprotech, cat. no. 450-10) c CRITICAL Stock aliquots should be stored at -80°C. One aliquot should be kept at 4°C to avoid multiple freeze/thaw cycles and used within 4 weeks.
• RA (retinoic acid; Sigma, cat. no. R2625) c CRITICAL Stock aliquots should be stored at -80°C. One aliquot should be kept at 4°C to avoid multiple freeze/thaw cycles and used within 4 weeks.
• SB431542 (R&D Systems, cat. no. 1614) c CRITICAL Stock aliquots should be stored at 4°C. Aliquots should be used within 8 weeks.
• Y-27632 dihydrochloride (Tocris Bioscience, cat. no. 1254) c CRITICAL Stock aliquots should be stored at -20°C. One aliquot should be kept at 4°C and used within 4 weeks.
• Matrigel hESC-qualified matrix, *LDEV-free (Corning, cat. no. 354277) • Vitronectin XF (Stemcell Technologies, cat. no. 07180)
• FN (fibronectin, human; Corning, cat. no. 356008) c CRITICAL Stock aliquots should be stored at -80°C. One aliquot should be kept at 4°C and used within 4 weeks.
• LM (laminin I, mouse; Cultrex, cat. no. 3400-010) c CRITICAL Stocks should be stored at -80°C. One aliquot should be kept at 4°C and used within 4 weeks • PO (poly-L-ornithine hydrobromide; Sigma, cat. no. P3655) c CRITICAL Stock aliquots should be stored at -80°C. One aliquot should be kept at 4°C and used within 4 weeks.
• 0.4% (wt/vol) trypan blue solution (Life Technologies, cat. no. 15250061) ! CAUTION Trypan blue is a suspected carcinogen and should be handled with care. Collect all materials exposed to trypan blue for disposal according to institutional guidelines.
• Gelatin (powder; Sigma, cat. no. G9391) Tables 1 and 2. c CRITICAL All solutions, including stock solutions, should be prepared under sterile conditions in a laminar flow hood to avoid contamination. c CRITICAL Avoid prolonged light exposure to culture media.
ESC medium: hPSC medium for maintenance in Steps 7A and 8A Combine 100 ml of KSR with 400 ml of DMEM/F12, with no glutamine. Add 5 ml of 200 mM Lglutamine and 5 ml of MEM nonessential amino acids (NEAAs). Filter-sterilize, then add 10 ng ml Mouse embryonic fibroblast (MEF) medium: MEF culture medium for Steps 7A and 8A Combine 100 ml of FBS with 900 ml of DMEM. Filter-sterilize before use. Store at 4°C (use within 3 weeks).
KSR medium: early ENC differentiation medium for Step 8A Combine 410 ml of knockout DMEM, 75 ml of KSR, 5 ml of 200 mM L-glutamine, 5 ml of MEM NEAAs, and 500 μl of 2-mercaptoethanol. Store at 4°C (use within 3 weeks).
N2 medium: late ENC differentiation medium for Step 8A Dissolve one bag of DMEM/F12 powder in 550 ml of dH 2 O. Add 1.55 g of glucose, 2.00 g of sodium bicarbonate, 16.1 μg of putrescine, 32 μg of progesterone, 5.2 μg of sodium selenite, 100 mg of transferrin, and 25 mg of insulin (dissolved in 10 ml of 5 mM NaOH). Add double-deionized H 2 O (with a resistance of 18.2 M) to a final volume of 1,000 ml. Filter-sterilize and store at 4°C (use within 3 weeks).
E8-C: hPSC medium for maintenance in Steps 7B and 8B Combine Essential 8-Flex supplement (20 μl ml −1 ) with Essential 8 Flex medium. Store at 4°C (use within 2 weeks).
Cocktail A: the first ENC differentiation medium in Step 8B Combine BMP4 (1 ng ml −1 ), SB431542 (10 μM), and CHIR 99021 (600 nM) with Essential 6 medium. Store at 4°C (use within 2 weeks).
Cocktail B: the second ENC differentiation medium in Step 8B Combine SB431542 (10 μM) and CHIR 99021 (1.5 μM) with Essential 6 medium. Store at 4°C (use within 2 weeks).
Cocktail C: the third ENC differentiation medium in Step 8B Combine SB431542 (10 μM), CHIR 99021 (1.5 μM), and RA (1 μM) with Essential 6 medium. Store at 4°C (use within 2 weeks).
NC-C: ENC medium for spheroid maintenance for both options in Step 8 Combine FGF2 (10 ng ml −1 ), CHIR 99021 (3 μM), N2 supplement (10 μl ml −1 ), B27 supplement (20 μl ml −1 ), glutagro (10 μl ml −1 ), and MEM NEAAs (10 μl ml −1 ) with neurobasal medium. Store at 4°C (use within 2 weeks). EN-C: ENC medium for differentiation and maintenance in Steps 8A and 8B Combine GDNF (10 ng ml −1 ), ascorbic acid (100 μM), N2 supplement (10 μl ml −1 ), B27 supplement (20 μl ml −1 ), glutagro (10 μl ml −1 ), and MEM NEAAs (10 μl ml −1 ) with neurobasal medium. Store at 4°C (use within 2 weeks).
EDTA 1× for passaging hESCs
Combine EDTA (500 μM) with PBS.
Matrigel (500-μl aliquots) Thaw a frozen vial of Matrigel overnight at 4°C. Prepare 500-μl aliquots in 50-ml conical tubes using chilled pipette tips, and keep them frozen at −20°C. c CRITICAL Matrigel must be kept cold to prevent gelatinization. Chill 50-ml centrifuge tubes at 4°C for 1 h before preparing aliquots of Matrigel. Matrigel-coated plates for use in both options in Steps 7 and 8 Dilute a 500-μl frozen aliquot of Matrigel in 50 ml of cold DMEM:F12. Pipette up and down vigorously with a 25-ml or 50-ml serological pipette to break the frozen Matrigel pellet. Coat the wells with the diluted Matrigel solution (100 µl per square centimeter of well surface area) and let them stand in a 37°C incubator overnight. Aspirate the Matrigel solution before plating hPSCs. c CRITICAL To achieve a fully defined system, substitute Matrigel-coated plates with vitronectin-coated plates.
Vitronectin-coated plates for use in Step 7B Dilute vitronectin (10 μl ml . Combine Y-27632 dihydrochloride (10 μM) with E8-C in a separate conical tube. Use this medium to break the cell pellet after centrifugation and initial plating. Aspirate Y-27632-dihydrochloride-supplemented medium from the wells 3-5 h after plating, and replace it with fresh E8-C. Prolonged ROCK inhibition may adversely affect pluripotency and differentiation 29 . 6 Incubate the cells in a cell culture incubator at 5% CO 2 and 37°C. Proceed by expanding colonies as described in the next stage of the protocol when cells approach confluency.
Maintaining hPSC cultures
c CRITICAL Before attempting the induction of ENC cells, it is important to first become comfortable in maintaining cultures of hPSCs (Step 7). Also, newly thawed lines should be passaged several times before differentiation. 7 Passage hPSCs several times before differentiation, using either our previously published procedure (option A) or fully defined conditions (option B). c CRITICAL STEP After the first two to three passages after thawing, several wells of hPSCs should be refrozen to maintain back-up stocks, as described in the Amsbio protocol provided with Stem-CellBanker. (A) Feeder-cell-based method (i) On the day of passaging, aspirate hESC medium from hPSC culture and add PBS (10 ml/ 10-cm dish). Gently rock the dish to wash cultures, and aspirate off PBS. (ii) Add collagenase IV (2 ml/10-cm dish) and incubate at room temperature for 10 min. (iii) Aspirate collagenase IV and add PBS (10 ml/10-cm dish). Gently rock the dish to wash colonies, and aspirate off PBS. (iv) Use a cell scraper to displace colonies from the culture surface. (v) Resuspend the detached colonies in 1 ml of hESC medium and pipette up and down to dissociate larger colonies. (vi) Add an appropriate volume of colony suspension with enough hESC medium for replating.
The optimal volume of colony suspension will depend on the confluency of cultures and passaging ratio. For new users, a passaging ratio of 1:6 is advised. Add this volume of cell suspension to 10 ml of ES cell medium for each new plate (e.g., add 160 μl of cell suspension to 10 ml of ES cell medium for each new 10-cm dish). (vii) Aspirate MEF medium from the cultured MEF dish and add ES cell suspension. (viii) Label the plate with cell line, date, and new passage number. Incubate at 5% CO 2 and 37°C.
(ix) Passage hPSC cultures once a week by repeating Step 7A(i-vii) when they reach~80% confluency. For continued maintenance, passaging ratios generally vary between 1:6 and 1:12 (i.e., resuspend the pellet of cells collected from one well at~80% confluency with 12 ml of fresh hESC medium, and add 2 ml of this suspension to each well of a new six-well plate). (B) Feeder-free method (i) Aspirate old E8-C medium from the corner of a well using a sterile pipette tip. Add fresh E8-C (200 μl per square centimeter of well surface area). Replace the medium with fresh E8-C every other day. (ii) When colonies are~80% confluent, begin the passage by aspirating E8-C from the corner of a single well. (iii) Add PBS (100 μl per square centimeter of well surface area) and gently rock the plate to wash off loose debris. Aspirate PBS using a sterile pipette tip. (iv) Add EDTA 1× (100 μl per square centimeter of well surface area). Replace the lid of the plate and watch through an inverted microscope for detachment of edges of colonies from the well surface (2-4 min).
(v) Use a P1000 micropipette or a 5-ml serological pipette to mechanically collect colonies from the well. Transfer EDTA 1× cell suspension to a 15-ml conical tube. c CRITICAL STEP Pipetting too vigorously may lead to excessive colony dissociation and adversely affect cell viability. The total time in EDTA 1× and the pipetting technique should be optimized to maintain cell viability. confluency. For continued maintenance, passaging ratios generally vary between 1:12 and 1:18 (i.e., resuspend the pellet of cells collected from one well at~80% confluency with 2-3 ml of E8-C and transfer 1 ml of this suspension to a new 15-ml conical tube. Add fresh E8-C to the new tube to bring the total volume to 12 ml. Add 2 ml of this suspension to each well of a new six-well plate).
ENC induction (days 0-12)
8 Once a consistent base of hPSC maintenance techniques has been established, initate ENC induction by replating the cells and replacing maintenance medium with differentiation medium, as described below in option A for our published method or option B using defined inducers. Induction proceeds gradually over an 11-to 12-d period of stepwise transitions in culture conditions (Fig. 2a) . (B) New chemically defined method (i) Day 2: replating hPSCs for differentiation. Two days before ENC induction, aspirate E8-C from hPSC cultures and use the same passage technique as described in Step 2, but use a 5:6 passaging ratio (i.e., all cells from five wells to a new six-well plate) and leave in EDTA for 3-5 min for increased cell separation. ? TROUBLESHOOTING (ii) Feed the cells with E8-C. Cells will continue to propagate, and after 2 d, the culture should become nearly confluent as a monolayer (Fig. 2b) while maintaining typical hPSC morphology ( Supplementary Fig. 2 ). (Fig. 2d) . ENC lineages are confirmed by the expression of HoxB2, HoxB5, and PAX3 (Fig. 2e) . Optional purification of ENC populations can be done by FACS using CD49D surface marker staining (Box 1). c CRITICAL STEP Given the increased risk of microbial contamination during the optional FACS purification step, collected cells may be fed with NC-C supplemented with Normocin (1 μl ml −1 ). Antimicrobial-supplemented medium should be used for a minimum of 2 d.
ENC spheroid formation (days 12-15)
c CRITICAL After 11-12 d of the ENC induction phase (Step 8), both option paths converge at the ENC spheroid phase. ENC monolayers are detached from the well surface and transferred to ultra-low-attachment plates to form free-floating 3D spheroids. Spheroids are maintained in NC-C medium for 3-4 d as part of an NC maintenance process (Fig. 3a) . 9 On day 11 or 12, aspirate cocktail C from the ENC induction phase plate using a sterile pipette tip. Add Accutase (100 μl per square centimeter of well surface area). Incubate for 30 min at 37°C and 5% CO 2 . 10 Do not aspirate Accutase. Add NC-C (100 μl per square centimeter of well surface area). Use a serological pipette to mechanically harvest cells from the surface of the well. Add the cell suspension to a 15-ml conical tube. 11 Centrifuge the conical tube at 290g for 1 min at room temperature (20-25°C). 12 With a sterile pipette tip, carefully aspirate as much supernatant as possible while avoiding the cell pellet. 13 Resuspend the pellet with an appropriate volume of NC-C and transfer the cell suspension to an ultra-low-attachment six-well plate (2 ml per well). 10 cm 2 of ENC monolayer is transferred to one
Box 1 | Purification of NC by FACS
After 12 d of ENC induction under
Step 8B, FACS can be used to prepare purified populations of NC cells. Previous NC induction protocols have suggested using p75/HNK1 marker staining for FACS analysis 11, 13 . However, p75 expression is found outside of the ENC, and a portion of p75-HNK1 double-positive cells have been shown to be SOX10::GFP-positive 12 . We have demonstrated that CD49D (α4 integrin) is a specific marker for SOX10 + hPSCderived NC lineages 16 . Here we present a procedure for the purification of ENC cells by FACS using CD49D. FACS purification is particularly recommended for experiments and assays that involve early ENC progenitors (day 11). The maintenance of 3D spheroid culture conditions is generally sufficient to enhance the purity of NC cells and neurons in the later stages of differentiation, without the need for further FACS purification (Fig. 7) . ) with DMEM/F-12, no glutamine. Add Pe/Cy7 anti-human CD49D antibody (1.25 μl ml −1 ). Prepare 2.4 ml per six-well plate of ENC differentiations (400 μl per well). c CRITICAL The staining medium should be made fresh and cannot be stored.
Reagents
Sorting medium
Dissolve BSA (0.02 mg ml −1 ) with DMEM/F-12, no glutamine. Sorting medium can be stored at 4°C for up to 4 weeks.
Procedure
1 On day 12 of ENC induction, aspirate cocktail C from the ENC induction plate using a sterile pipette tip. Add Accutase (100 μl per square centimeter of well surface area). Incubate at 5% CO 2 and 37°C for 30 min. 2 Do not aspirate Accutase. Use a serological pipette to mechanically collect cells from the surface of the well.
Add the cell suspension to a 15-ml conical tube. 3 Centrifuge the conical tube at 290g for 1 min at room temperature (20-25°C). With a sterile pipette tip, carefully aspirate as much supernatant as possible while avoiding contact with the cell pellet. 4 Resuspend the pellet with freshly prepared staining medium (400 μl for every well of a six-well plate collected). 5 Place the conical tube of the cell suspension in ice for 20 min. 6 After 20 min, centrifuge the conical tube at 290g for 1 min at room temperature (20-25°C). With a sterile pipette tip, carefully aspirate as much supernatant as possible while avoiding contact with the cell pellet. 7 Resuspend the pellet with freshly prepared sorting medium (~1 ml in total). Add DAPI (1 μl ml −1 ). 8 Transfer the stained cell suspension through the cell strainer cap to a 5-ml round-bottom test tube for FACS. 9 FACS settings may vary per user. Collect the CD49D + population in a sterile 5-ml round-bottom test tube and cap. An example gating strategy is provided in Supplementary Fig. 6 . 10 Centrifuge the test tube at 290g for 1 min at room temperature (20-25°C). With a sterile pipette tip, carefully aspirate as much supernatant as possible while avoiding contact with the cell pellet. 11 Resuspend the pellet with NC-C (1 ml per each 10 6 cells) and transfer the suspension to an ultra-lowattachment six-well plate (2 ml per well). Incubate at 37°C and 5% CO 2 . 12 Resume the protocol at Step 9 of the main Procedure (under 'ENC spheroid formation').
well of an ultra-low-attachment six-well plate (a six-well ENC induction plate corresponds to a sixwell ultra-low-attachment plate). Incubate at 37°C and 5% CO 2 for 2 d. 3D spheroids will continue to congregate during this period. 14 After a 2-d incubation period (days [13] [14] , 3D spheroids should be observable. Gently swirl ultralow-attachment plates to group the free-floating spheroids into the center of each well. Using a P1000 micropipette, slowly aspirate the old NC-C by moving around the circumference of a well, actively avoiding any removal of spheroids. 15 Add 2 ml of fresh NC-C to each ultra-low-attachment plate well. Incubate at 37°C and 5% CO 2 for an additional 24 h. Examples of 3D spheres at day 14 are shown in Fig. 3b . ? TROUBLESHOOTING
EN induction phase (day 15)
c CRITICAL After the ENC spheroid phase (Steps 9-15) and 15 total days from the start of ENC differentiation, ENC spheroids are dissociated with Accutase treatment and replated on PO/LM/FNcoated wells. This stage marks the final replating of the protocol and the beginning of EN induction (Fig. 4a) . 16 On day 15, gently swirl ultra-low-attachment plates to group the free-floating spheroids into the center of a well. Using a P1000 micropipette, slowly remove the old NC-C from the circumference of a well, while actively avoiding any removal of spheroids. 17 Add Accutase (1 ml) to each well and incubate for 30 min at 37°C and 5% CO 2 . 18 Use a 5-ml serological pipette to gently dissociate the remaining spheroids by two to three rounds of pipetting. Transfer the cell suspension to a 50-ml conical tube. c CRITICAL STEP Dissociation of spheroids using a P1000 micropipette adds an element of shear stress and may lead to excessive cell death. The use of a serological pipette is recommended owing to the larger diameter of the tip opening. 19 Centrifuge the conical tube at 290g for 1 min at room temperature (20-25°C). 20 Carefully aspirate the supernatant using a sterile pipette tip while avoiding contact with the cell pellet. 21 Resuspend the pellet in 10 ml of EN-C. 22 Determine the viable cell concentration using a hemocytometer and trypan blue. 23 Add the remaining volume of EN-C necessary to replate the cell suspension at~100,000 cells per square centimeter of surface area to the conical tube. 24 Aspirate the FN/laminin/PBS solution from wells using a sterile pipette tip. 25 Add the EN-C cell suspension to the center of the well or a dish. 26 Incubate at 37°C and 5% CO 2 . Move the EN plates in a north/south/east/west direction after returning them to the incubator shelf to ensure an even distribution of cell attachment. 
Troubleshooting
Troubleshooting advice can be found in Table 3 .
Timing
Steps 1-6, thawing and plating hPSCs: 15 min
Step 7, passaging hPSCs for maintenance: 15 min
Step 8A(i-iv) and 8B(i and ii), passaging hPSCs for ENC induction: 15 min
Step 8A(v-x) and 8B(iii-ix), ENC induction medium changes: 5 min Fig. 3a ,b) and stay viable for several weeks ( Supplementary Fig. 3c,e) . A major factor in maintaining long-term neuronal cultures is reducing the stress associated with the replacement of culture medium. For cultures older than 50 d, users should wait until the culture medium turns yellow, and carefully replace the medium with FN/LM-supplemented medium. Cultures lasting longer than 100 d can be achieved with this protocol. Neuronal identity should be confirmed through marker expression and relative gene expression analysis by qRT-PCR. Reducing the emergence of contaminating, nonneuronal cell types can be a challenge, and continued optimization of the protocol should reduce this. The identification of CD49D (α4 integrin) as a reliable surface marker of SOX10 + NC lineages 16 enables the assessment of the ENC induction efficiency and the cells' prospective isolation. We analyzed CD49D expression after 12 and 15 d of differentiation under option B (Step 8) for two additional hPSC lines (hESC-UCSF4 and hiPSC-WTC11) (Fig. 4b,c) . The results demonstrated initial variation in ENC induction efficiency between cell lines and validated the ENC spheroid phase (days 12-15) as necessary for the enrichment of CD49D + EN precursors (Fig. 4c) . After EN induction, neuronal identity is verified on the basis of coexpression of pan-neuronal marker TUJ1 and the EN-precursor-specific marker TRKC (Fig. 4d,e) . Additional neuronal-subtype-specific markers Gently separate large, irregularly shaped bodies into smaller spheroids by pipetting them up and down two to three times with a P1000 micropipette include the cholinergic neuronal marker choline acetyl transferase (CHAT), serotonin (5-HT), gamma-aminobutyric acid (GABA), and neuronal nitric oxide synthase, which labels nitric oxide (NO)-producing neurons (Fig. 4f,g ). Coexpression analysis of CHAT and NOS1 revealed a separate population of cholinergic and nitrergic neurons in the differentiated culture ( Supplementary Fig. 4 ). Glial cells expressing glial fibrillary acidic protein (GFAP) and SOX10 also emerge in differentiated cultures at the later stages of the EN induction step (Fig. 5) .
Comparisons of relative gene expression between samples collected at separate time points during differentiation revealed population-level transitions in gene expression that are supported by previous 
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descriptions of the transcriptional processes of in vivo ENS development 30 . High expression levels of ENC-derived progenitor markers PHOX2B, ASCL1, and EDNRB during the transition to EN induction revealed the presence of enteric precursors (Fig. 6a-c) . The synchronous downregulation of precursor markers with upregulation of TUJ1 and CHAT illustrates neuronal commitments and maturity taking place over the course of EN induction (Fig. 6d,e) . Additionally, the delayed emergence of enteric glia is reflected in the increased expression of glial marker GFAP in the later stages of the EN induction phase (Fig. 6f) .
The primary contaminating cell types found in differentiations are NC-derived flat myofibroblastlike cells identifiable by expression of smooth muscle actin (SMA) (Supplementary Fig. 5 ). These contaminants are particularly unfavorable to the longevity of mature EN, as they catalyze the eventual detachment of neurons from the well surface, resulting in apoptosis. Minimizing the number of cells expressing SMA represents a straightforward approach to further optimize the protocol and maximize the overall durability of EN populations.
CD49D -PE-Cy7
Unstained CD49D -PE-Cy7 
Data availability
The data generated or analyzed during this study are included in this published article (and its Supplementary Information files). 
